13.07.2015 Views

Guidelines for Complications of Cancer Treatment Vol VIII Part B

Guidelines for Complications of Cancer Treatment Vol VIII Part B

Guidelines for Complications of Cancer Treatment Vol VIII Part B

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

eceived elective nodal irradiation (ENI). Their treatment planswere subsequently recapitulated using a three-dimensionaltreatment planning system. Twenty patients were planned usingthis system from the outset. For these patients, elective nodalirradiation was omitted. Dose-volume histograms (DVH) wereconstructed and several parameters analyzed <strong>for</strong> their abilityto predict <strong>for</strong> the development <strong>of</strong> pneumonitis. RESULTS:Univariate analysis revealed that the percentage lung volumereceiving more than 20 Gy (V20) and the mean lung dose are<strong>of</strong> predictive value <strong>for</strong> the development <strong>of</strong> pneumonitis afterCHART. There is a strong correlation between these twoparameters. Importantly, partial volume lung irradiation usingCHART appears to be better tolerated than conventionallyfractionated radiotherapy. The omission <strong>of</strong> ENI considerablyreduces V20. Using a commonly employed 3-beam techniqueit was also noted that the shape <strong>of</strong> the planning target volume(PTV) in the transverse plane (expressed as an elliptical index)affects the con<strong>for</strong>mity <strong>of</strong> the V20 isodose to the PTV. Thisinfluences the scope <strong>for</strong> dose escalation with irregularly shapedtumors.CONCLUSIONS: In relation to acute radiation pneumonitis,CHART appears to have a superior therapeutic index thanconventionally fractionated radiotherapy. V20 and mean lungdose are useful factors <strong>for</strong> predicting the risk <strong>of</strong> thiscomplication. The use <strong>of</strong> these parameters will aid the selection<strong>of</strong> optimal treatment plans and provides a basis <strong>for</strong> future doseescalation studies.Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):323-9.Clinical dose-volume histogram analysis <strong>for</strong> pneumonitis after3D treatment <strong>for</strong> non-small cell lung cancer (NSCLC).325

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!